Drugs / Thymosin-α
Thymosin-α
English name Thymosin-alpha1
Trials 2
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 4 | NCT01943617 | Jun 2013 → Dec 2016 | cirrhosis of liver | Beijing Friendship Hospital | Completed | No outcome recorded |
| Phase 4 | NCT01938820 | Jun 2013 → Dec 2016 | cirrhosis of liver | Beijing Friendship Hospital | Completed | No outcome recorded |
Evidence & citations 4 cited values
Every value below carries the sentence it was read from. 3 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Thymosin-α | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01943617 ↗ |
| Known as | Thy-α1 | “Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).” PMID 33460002 ↗ Jan 2021 |
| Known as | thymosin-alpha1 | “Patients were treated with entecavir (ETV) or ETV + thymosin-alpha1 (Thy-α1) or lamivudine (LAM) + adefovir (ADV).” PMID 33460002 ↗ Jan 2021 |
| Route | Other | “Thymosin-α 1.6μg, Twice a week, ih, in the middle one year” NCT01943617 ↗ |